Jefferies analyst Chris Howerton lowered his price target for TherapeuticsMD to $4 from $5 saying the company reported “weak” Q1 results with Imvexxy sales missing expectations. The analyst keeps a Hold rating on the shares.
https://thefly.com/landingPageNews.php?id=2904799
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.